The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 353:1630-1631 October 13, 2005 Number 15
NextNext

Treatment of HBeAg-Positive Hepatitis B with Peginterferon and Lamivudine

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Lau, G. K.K.
-PubMed Citation
To the Editor: Lau et al. (June 30 issue)1 studied pegylated interferon for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Overall, HBeAg seroconversion was highest among patients treated with pegylated interferon monotherapy, despite the more potent hepatitis B virus (HBV) DNA suppression with lamivudine at 48 weeks. Although viral suppression and HBeAg seroconversion are well correlated,2 the degree of viral suppression needed for seroconversion to occur is not well defined. With regard to this study, it would be of interest to know what the degree of HBV DNA suppression was among patients in whom HBeAg or . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.